Search

What is SCERTS?

In this blog, Senior Speech Pathologist Sally Grauaug and Speech Pathology Clinical Lead Aria May discuss the model SCERTS and how it can support your child's communication level.

The Sun Safe app: a new online tool to promote safe sun behaviours by teenagers

Gail Prue Shelley Alvares Hart Gorman PhD BSc (Hons) MSc PhD BSc (Hons) PhD Principal Research Fellow Honorary Research Fellow Honorary Research

Psychometric validation of the quality of life Inventory − Disability (QI-Disability) among patients with Lennox-Gastaut syndrome and Dravet syndrome

To evaluate the psychometric properties of the Quality of Life Inventory -Disability (QI-Disability) for individuals with Dravet syndrome (DS) or Lennox-Gastaut syndrome (LGS), two rare developmental and epileptic encephalopathy conditions.

Caregiver-reported quality of life in individuals with developmental and epileptic encephalopathy and other severe neurodevelopmental encephalopathies

Information on factors contributing to quality of life (QOL) informs meaningful patient-centred care. We evaluated factors influencing QOL in individuals with developmental and epileptic encephalopathy (DEE) and other severe neurodevelopmental encephalopathy conditions using hypothesis-free regression tree analysis.

Co-designing a new clinical pathway to support families with children identified as having early-stage type 1 diabetes in Western Australia

Children with early-stage (pre-symptomatic) type 1 diabetes are currently identified primarily via research-based screening programmes in Australia. Once identified, families live with the knowledge that their child has an increased chance of developing symptomatic, lifelong, insulin-requiring type 1 diabetes but have no specific clinical pathway available to them in Western Australia for accessing tailored support or education. This project aimed to co-design a new clinical pathway to address this unmet need.

Confident and Trustworthy Model for Fidgety Movement Classification

General movements (GMs) are part of the spontaneous movement repertoire and are present from early fetal life onwards up to age five months. GMs are connected to infants' neurological development and can be qualitatively assessed via the General Movement Assessment. In particular, between the age of three to five months, typically developing infants produce fidgety movements and their absence provides strong evidence for the presence of cerebral palsy.

Glycemic and Psychosocial Outcomes of Advanced Hybrid Closed-Loop Therapy in Youth With High HbA1c: A Randomized Clinical Trial

To determine the efficacy of advanced hybrid closed-loop therapy in a high-risk cohort of youth on continuous subcutaneous insulin infusion with or without continuous glucose monitoring with suboptimal glycemia.

Effects of ganaxolone on non-seizure outcomes in CDKL5 Deficiency Disorder: Double-blind placebo-controlled randomized trial

CDKL5 deficiency disorder (CDD) is a rare developmental and epileptic encephalopathy. Ganaxolone, a neuroactive steroid, reduces the frequency of major motor seizures in children with CDD. This analysis explored the effect of ganaxolone on non-seizure outcomes. 

General Movement Assessment in infancy and later cognitive outcomes: A systematic review and meta-analysis

To evaluate whether the General Movement Assessment in infancy is associated with later cognitive outcomes from early childhood through adulthood.

Understanding parents' perspectives of repeated blinded continuous glucose monitoring in children with early-stage type 1 diabetes and an affected first-degree relative

To explore the lived experiences of parents of children at risk of type 1 diabetes undergoing repeated blinded continuous glucose monitoring. Since 2021, children with persistent islet autoimmunity in the Environmental Determinants of Islet Autoimmunity study have been invited to participate in a sub-study involving blinded Dexcom G6 CGM.